The Effect of Preoperative Inflammation-based Scores on Postoperative Morbidity and Mortality for Laparoscopic Gastrectomy
- Conditions
- Stomach Neoplasms
- Registration Number
- NCT02930291
- Lead Sponsor
- Fujian Medical University
- Brief Summary
The purpose of this study is to explore the effect of preoperative inflammation-based scores on postoperative morbidity and mortality for laparoscopic gastrectomy.
- Detailed Description
A prospective cohort study will be performed to explore the effect of preoperative inflammation-based scores on postoperative morbidity and mortality for laparoscopic gastrectomy.The evaluation parameters are perioperative clinical efficacy, postoperative complications and 3-year survival and recurrence rates.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 310
Age from 18 to 75 years
- Primary lower third gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy
- cT2-4a, N0-3, M0 at preoperative evaluation according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual Seventh Edition
- No distant metastasis is observed. And the spleen, pancreas or other adjacent organs are not involved by the tumor.
- Performance status of 0 or 1 on Eastern Cooperative Oncology Group scale (ECOG)
- American Society of Anesthesiology score (ASA) class I, II, or III
- Written informed consent
• Women during pregnancy or breast-feeding
- Severe mental disorder
- History of previous upper abdominal surgery (except laparoscopic cholecystectomy)
- History of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal dissection
- Enlarged or bulky regional lymph node envelop important vessels
- History of other malignant disease within past five years
- History of previous neoadjuvant chemotherapy or radiotherapy
- History of unstable angina or myocardial infarction within past six months
- History of cerebrovascular accident within past six months
- History of continuous systematic administration of corticosteroids within one month
- Requirement of simultaneous surgery for other disease
- Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer
- FEV1<50% of predicted values
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 3-year disease free survival rate 36 months
- Secondary Outcome Measures
Name Time Method The variation of cholesterol 12 months The variation of cholesterol on postoperative 3, 6, 9 and 12 months
3-year recurrence pattern 36 months The amount of abdominal drainage 10 days The variation of albumin 12 months The variation of albumin on postoperative 3, 6, 9 and 12 months
Morbidity and mortality 30 days; 36 months The early postoperative complication and mortality are defined as the event observed within 30 days after surgery, while the time frame for late complication is the period from postoperative day 31th to the end of month 36th.
The variation of weight 12 months The variation of weight on postoperative 3, 6, 9 and 12 months
The daily highest body temperature 7 day The daily highest body temperature before discharge
Time to first liquid diet 10 days Duration of hospital stay 10 days Time to soft diet 10 days The values of C-reactive protein Preoperative 3 days and postoperative 1, 3, and 5 days The values of C-reactive protein IN milligram/liter from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded to access the inflammatory and immune response.
The values of prealbumin Preoperative 3 days and postoperative 1, 3, and 5 days The values of prealbumin in gram/liter from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded to access the inflammatory and immune response.
3-year disease overall survival rate 36 months Time to first ambulation 10 days The data of postoperative recovery course.
Intraoperative lymph node dissection time 1 days intraoperative lymph node dissection time includes infrapyloric area lymph node,suprapancreatic area lymph
The values of white blood cell count Preoperative 3 days and postoperative 1, 3, and 5 days The values of white blood cell count from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded to access the inflammatory and immune response.
The values of platelet count Preoperative 3 days and postoperative 1, 3, and 5 days The values of platelet count from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded to access the inflammatory and immune response.
Visual Analog Score for pain 7 days the values of visual analog score for pain before operation and on postoperative day 1 to day 7 are recorded.
Blood transfusion 10 days The number of lymph node dissection 1 day Time to first flatus 10 days The number of positive lymph nodes 1 day Intraoperative morbidity rates 1 day The intraoperative postoperative morbidity rates are defined as the rates of event observed within operation.
The values of lymphocyte count Preoperative 3 days and postoperative 1, 3, and 5 days The values of lymphocyte count from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded to access the inflammatory and immune response.
The values of neutrophil differential count Preoperative 3 days and postoperative 1, 3, and 5 days The values of neutrophil differential count from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded to access the inflammatory and immune response.
The rate of conversion to laparotomy 1 day The results of endoscopy 12 months the results of endoscopy on postoperative 3 and 12 months
The values of hemoglobin Preoperative 3 days and postoperative 1, 3, and 5 days The values of hemoglobin in gram/liter from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded to access the inflammatory and immune response.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Fujian Medical University Union Hospital
🇨🇳Fuzhou, Fujian, China
Fujian Medical University Union Hospital🇨🇳Fuzhou, Fujian, China